Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 15/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13184701 | 0.95 | CYP3A4 (0.43) | CYP3A4CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL748454 | 0.90 | POLB (0.46) | CYP3A4CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL12037780 | 0.90 | MEN1 (0.49) | CYP3A4CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL744761 | 0.89 | CYP3A4 (0.44) | CYP3A4CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL13745230 | 0.89 | CYP3A4 (0.49) | CYP3A4 | |
| SCHEMBL12037483 | 0.89 | CNR1 (0.43) | CYP3A4CNR1CNR2 | |
| SCHEMBL12036587 | 0.89 | CNR1 (0.44) | CYP3A4CNR1CNR2 | |
| SCHEMBL746947 | 0.88 | MEN1 (0.41) | CYP3A4CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL14620156 | 0.88 | CYP3A4 (0.51) | CYP3A4 | |
| SCHEMBL12037546 | 0.87 | CNR1 (0.45) | CYP3A4CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | CYP3A4 4757/4885CYP2D6 4684/4885CYP2C9 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.